Finnish biopharma company Faron has entered into a licensing agreement with Pharmbio Korea for the development and commercialization of Traumakine (recombinant interferon beta-1a), it has been announced.
Traumakine, for the treatment of acute respiratory distress syndrome (ARDS), is Faron’s lead drug and is currently in the pivotal pan-European Phase III INTEREST trial.
Under the terms of the agreement Pharmbio will obtain exclusive Korean rights to Traumakine. Faron will receive an initial signing fee of 750,000 euros ($847,500) and additional, undisclosed development based milestones.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze